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Abstract: Four novel amicoumacins, namely lipoamicoumacins A–D (1–4), and one new 
bacilosarcin analog (5) were isolated from culture broth of a marine-derived bacterium 
Bacillus subtilis, together with six known amicoumacins. Their structures were elucidated 
on the basis of extensive spectroscopic (2D NNR, IR, CD and MS) analysis and in 
comparison with data in literature.  
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1. Introduction  
Highly diverse marine microbes not only act as a driving force of material cycles in the marine 
ecosystems but also serve as an excellent source of novel compounds with great potential for 
biomedical and ecological applications [1,2]. However, natural product discoveries from marine 
microbes in the Red Sea remain largely unexplored. Accordingly, we have recently initiated a program 
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to discover bioactive natural products from microorganisms isolated from some under-explored 
ecological niches in the Red Sea. Based on the cytotoxicity and antibacterial activities of the crude 
extract of its fermented broth, strain B1779, identified as Bacillus subtilis based on 16s DNA gene 
sequence, was chosen for further chemical investigation. Previous chemical studies of the Genus 
Bacillus have led to the isolation and identification of six isocoumarin type metabolites [3]. Some of 
these exhibit different biological activities, such as cytotoxic [4,5], antibacterial [5,6], antiulcer [7–9] 
and plant-growth inhibitory activities [10]. Our ongoing chemical investigation of B. subtilis strain 
B1779 resulted in the isolation of 11 amicoumacins, including four novel lipoamicoumacins that were 
designated as lipoamicoumacins A–D (1–4), one new bacisarcin C (5) and six known analogues (6–11). 
Compounds  6–7 showed significant cytotoxic activity against HeLa cells and strong antibacterial 
activities against Staphylococcus aureus and Loktanella hongkongensi. In this paper, we report the 
fermentation, isolation, structures elucidation, and cytotoxic and antibacterial activities of isolated 
compounds from a Bacillus subtilis strain B1779.  
2. Results and Discussion  
Strain Bacillus subtitlis B1779 was cultivated in a sea salt-based medium for 4 days with vigorous 
shaking (160 rpm). The UPLC-MS and bioassay guided fractionation revealed that the ethyl acetate 
(EtOAc) extract of its fermentation broth contained bioactive secondary metabolites with molecular 
weights ranging from m/z: 390 to 730. Moreover, analysis of the 
1H NMR and UV spectra of this 
extract revealed that the bioactive fractions were mainly comprised of isocoumacin-type compounds 
with characteristic spectral features and UV absorptions similar to those of amicoumcin A (7). Further 
separation with semi-preparative HPLC resulted in the isolation of 11 constituents with similar UV and 
NMR features, including five new compounds (1–5); their structures were determined on the basis of 
spectroscopic analysis and upon comparison with data in the literature. Compounds 1–4 were 
identified as novel lipo-amicoumacins, which are referred to herein as Lipoamicoumacin A–D (1–4). 
2.1. Structure Elucidation of New Amicoumacins 
Lipoamicoumacin A (1) was obtained as a white amorphous solid. Based on HRESIMS   
(m/z 703.3921 [M + H]
+) data we established its molecular formula as C36H54N4O10, indicating twelve 
degrees of unsaturation. The IR absorptions at 3432, 1667 and 1545 cm
−1 in association with the  
13C NMR spectroscopic data suggested the presence of hydroxyl, carbonyl and aromatic groups. The 
1H NMR spectra exhibited three aromatic proton singlets for a tri-substituted aromatic unit at δH 7.47 
(1H, dd, H-6), 6.85 (1H, d, H-7) and 6.81 (1H, d, H-5), three oxymethines at δH 4.79 (1H, t, H-9'), 4.68 
(1H, dd, H-3) and 4.42 (1H, d, H-8'), three nitrogen-bond methines at δH 4.51 (1H, dt, H-10'), 4.65 (1H, 
dd, H-15') and 4.29 (1H, m, H-5'), a broad peak at δH 1.30 (10H, brs, H4''~8'') and four methyl 
resonances at δH  0.97 (3H, d, H-2'), 0.89 (3H, d, H-1') and 0.88 (6H, d, H-11'', H-12''). The   
13C NMR spectra provided five ester/amide carbonyl resonances at δC (171.2–178.1), six aromatic 
carbons for a trisubstituted aromatic ring, three oxymethines and three nitrogen-bonded sp
3 carbons. In 
addition, the UV spectrum was nearly identical to that reported for amicoumacins (λmax 206, 247 and 
314 nm) [8], suggesting that 1 possessed a similar dihydroisocoumarin chromophore. The gross 
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NMR spectral data (Figures 1 and 2), indicating an amicoumacin unit was linked to a fatty acid chain. 
The NMR spectroscopic data of 1 were highly similar to those from the combination of amicoumacin 
C (9) and lipoamide B [8,11] with the exceptions of the Δδ = 1.6 ppm upfield shift of C-10' (δC 48.6) 
and Δδ = 0.23 ppm downfield shift of H-10' (δH 4.51). The differences were due to the linkage of the 
lipoamide group at C-10' in compound 1 when comparing it with 9. These assignments were also 
supported by HMBC correlations from H-10' to C-14' and ESI-MS fragmentations (Figure 3). The 
ESI-MS spectrum showed fragment ions corresponding to the loss of an acyl group from the iso C12 
fatty acid side strain (m/z 521) and sequential loss of asparagine (Asn) (m/z 407) and 
dihydroisocoumarin fragment ion (m/z 250). The relative configuration of 1 was determined by NOE 
correlations of H-3/H-4' and H-5'/H-8', which shares similar stereochemical configurations with 
amicoumacin C (9). To further confirm the absolute configuration of the dihydroisocoumarin unit, the 
CD spectrum of 1 and 9 was compared. The CD spectrum of 1 showed positive Cotton effects at 221 
and 240 nm and negative Cotton effects at 260 and 310 nm, which were in good agreement with those 
for compound 8 and 9 [9,10]. Thus, the structure of 1 was determined as illustrated in Figure 1.  
Figure 1. Amicoumacins (1–11) isolated from Bacillus subtilis strain B1779. 
 
Figure 2. Select HMBC and COSY correlations of lipoamicoumacin A (1). 
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Figure 3. ESI-MS fragmentations of lipoamicoumacins A–D (1–4). 
 
The molecular formula of lipoamicoumacin B (2) was established as C37H56N4O10, based on the 
HRESIMS (m/z 717.4062 [M + H]
+, calcd. 717.4069), which was 14 amu higher than that of 1. The 
NMR spectroscopic data of 2 (Supporting Information, Table 1) indicated that its structure was closely 
related to that of 1. The only difference was the presence of an additional methyl group (δH 0.86,  
δC 11.9) in 2, located at C-11''. HMBC correlation between H-12'' and C-10'' and COSY correlations 
from H-12'' to H-11'', H-11'' to H-10'' and H-10'' to H-13'' confirmed that the structure of 2 was a  
C-11'' methylated analog of 1, seen also with the ESIMS fragmentation analysis.  
Table 1. NMR data of lipoamicoumacins A (1). 
lipoamicoumacins A (1) 
Position  δC, mult  δH, (J in Hz)  HMBC  Position  δC, mult  δH, (J in Hz)  HMBC 
1  171.2, C      11'  36.7, CH2  2.45, dd (2.6, 18.0), 3.01 m  12' 
3  82.7, CH  4.68, m  1  12'  178.1, C     
4 30.8,  CH2 
2.98, dd (3.5, 16.0),  
3.06, m 
5, 9, 10      Asparagine   
5  119.8, CH  6.81, d (7.6)  4, 7, 9  14'  173.3, C     
6  137.8, CH  7.47, dd (7.5, 8.4)  8, 10  15'  51.3, CH  4.65, dd (6.5, 7.0)  14', 1'' 
7  116.9, CH  6.85, d (8.4)  5, 8, 9  16'  38.2, CH2 
2.57, dd (7.1, 15.2), 2.67,  
dd (6.4,15.2) 
14', 17' 
8  163.3, C      17'  174.8, C     
9 109.6,  C      18'       
10 141.4,  C          Fatty  acid   
1' 22.1,  CH3  0.89, d (6.6)  2', 4'  1''  176.3, C     
2' 24.0,  CH3  0.97, d (6.6)  1', 4'  2''  37.0, CH2  2.24, t (8.0)  1'' 
3' 26.0,  CH3  1.68, m    3''  27.0, CH2 1.60,  m   
4' 40.4,  CH2  1.43, m, 1.82, m    4''~8''  30.5–31.2  1.30, brs   
5'  50.7, CH  4.29, m  7'  9''  38.3, CH2  1.17 m, 1.30 m   
7'  172.8, C      10''  27.0, CH  1.53 m   
8'  73.6, CH  4.42, d (2.5)  7', 10'  11''  23.2, CH3  0.88, t (6.8)  9'' 
9'  87.9, CH  4.79, t (2.4)  7', 12'  12''  23.2, CH3  0.88, t (6.8)  9'' 
10'  48.6, CH  4.51, dt (9.1, 2.0)  14'         
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Lipoamicoumacin C (3) had a molecular formula of C37H56N4O10, which was established by   
the HRESIMS data (m/z 717.4062 [M + H]
+, calcd. 717.4069). The NMR data of 3 (Supporting 
Information, Table 1) were comparable to those of 1, with the exception of an additional methylene at 
δH 2.25 (2H, t, H-17') and the Δδ = 3.1 ppm downfield shift of C-18' (δC 177.8). Analysis of ESIMS 
fragmentation ions (Figure 3) revealed the presence of a glutamine group (∆m/z 535–407) in 3, instead 
of an asparagine group (∆m/z 521–407) in 1. The suggestion was further confirmed by HMBC 
correlations of H-10'/C-14', H-15'/C-1'' and 
1H–
1H COSY correlations of H-17'/H-16' and H-16'/H-15'. 
Lipoamicoumacin D (4) had a molecular formula of C38H58N4O10, which was established from the 
HRESIMS (m/z 731.4215 [M + H]
+, calcd. 731.4222). The molecular weight of 4 was also 14 amu 
higher than that of 3. The NMR and MS spectroscopic data of 4 indicated that its structure is nearly 
identical to that of 3, with the exception of an additional methyl group located at C-11'' in 4.  
Bacilosarcin C (5) had a molecular formula of C24H34N2O9, which was established from the 
HRESIMS (m/z 495.2344 [M + H]
+, calcd. 495.2337). The 
1H NMR spectrum exhibited three aromatic 
proton singlets for one aromatic spin system at δH 7.46 (1H, dd, H-6), 6.85 (1H, d, H-7) and 6.82 (1H, 
d, H-5), three oxymethines at δH 4.68 (1H, dd, H-9'), 4.66 (1H, dd, H-3) and 4.14 (1H, d, H-8'), two 
nitrogen-bonded methines at δH 4.34 (1H, dt, H-5'), 3.91 (1H, m, H-10') and 3.43 (1H, q, H-14'), two 
methylenes at δH 3.10 (1H, dd, H-4) and 2.96 (1H, dd, H-4), δH 3.06 (1H, dd, H-11') and 2.92 (1H, dd, 
H-11'), and four methyl resonances at δH 1.28 (3H, d, H-13'), 1.26 (3H, s, H-16'), 0.98 (3H, d,   
H-2') and 0.94 (3H, d, H-1'). The UV absorptions at λmax 206, 247 and 314 nm in association with the 
NMR data suggested that compound 5 also possesses an amicoumacin unit. The NMR data of 5 
(Supporting Information, Table 2) were mostly the same as bacilosarcin B (6) [10], except for the  
Δδ = 0.20 ppm downfield shift of H-11' (δH 3.06). The difference was due to the linkage of a hydroxyl 
group (5) as opposed to an amide group (6) at C-12'. These assignments were also supported by 
molecular composition and a HRESI-MS fragment ion (m/z: 477.2238 [M − H2O + H]
+) corresponding 
to the intermolecular dehydration between C-9' and C-12'. The relative configurations of 5 were 
determined by the NOE correlations of H-4'/H-9', H-12'/H-8' and H-12'/14', which were in good 
agreement with those for compound 6. The stereochemistry of 5 was assigned to be the same as that of 
6 based on their similar Cotton effects observed in the CD spectrum and similar levo specific rotation. 
Based on spectroscopic analyses and the comparison of their spectroscopic data with those reported 
in the literature, six known compounds were identified as bacilosarcin B (6) [10], amicoumacin A–C  
(7–9) [6,9], 6-[[1-(3,4-dihydro-8-methoxy-l-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-4,5-
dihydroxy-6-oxo-3-ammoniohexanoate (10) and AI-77-F (11) [8]. 
2.2. Biological Evaluation 
All isolated compounds were evaluated for their cytotoxicity against human cervical carcinoma 
epithelioid cell line HeLa using MTT methods, and for their antibacterial activities against 
Staphylococcus aureus, Bacillus subtilis, Loktanella hongkongensis, Peseudomonas aeruginosa and 
Chromobacterium violaceum by MIC assay .Only compounds amicoumacin A (7) and bacilosarcin B 
(6), which have an amide functional group at C-12', exhibited cytotoxicity against the HeLa cells with 
IC50 values of 33.60 and 4.32 μM respectively, indicating that the C-12' amide group of amicoumcin Mar. Drugs 2012, 10 324 
 
 
plays a critical role in cytotoxicity. This was further supported by comparision of cytotoxicity between 
compounds 7 and 8 and between compounds 5 and 6. Compound 7, with an IC50 value of 4.32 μM 
showed 30-fold higher cytotoxicity than 8. Previous research also reported that C-12 amide groups of 
amicoumacin played a critical role in antibacterial activities against methicillin-resistant 
Staphylococcus aureus (MRSA) [12], which was based on the comparison of amicoumacin A (7) and 
amicoumacin B (8). Herein, we studied the antibacterial structure-activity relationships based on 11 
amicoumacins against three target bacterial strains. Our results indicate that only those compounds 
with C-12' amide groups exhibited antibacterial activities against B. subtilis,  S. aureus and  
L. hongkongensis (Supporting Information, Table 3), which strongly supported that the C-12' amide 
group of amicoumcin acts as a pharmacophore in antibacterial activities. This conclusion was further 
supported by comparing antibacterial activities between compounds 7 and 8 and between compound 5 
and  6. Compound 7 exhibited antibacterial activities against B. subtilis,  S.  aureus and   
L. hongkongensis, which were about six-fold higher than those of compound 8.  
While microbial secondary metabolites have been extensively used as antimicrobial or antitumor 
therapeutic agents, the biological functions of the metabolites in microbes that produce them have only 
been studied in a few cases. For instance, xenocoumacin-1, the major antimicrobial compound 
produced by Xenorhabdus nematophila, was shown to suppress their competitors of the host and 
subsequently convert xenocoumacin-2, which has a much weaker antimicrobial activity, to avoid   
self-toxicity [13]. In Bacillus genus, surfactins were produced to serve as signaling molecules to 
activate the pathway related to biofilm information [14], while sporulenes was shown to serve as a 
chemical barrier against oxidative stress [15]. However, the biological role of amicoumacins in the life 
cycle of B. subtillis is far from being understood. It will therefore be intriguing to investigate the 
chemical ecology of amicoumacins in the future. 
3. Experimental Section  
3.1. General Experimental Procedures 
Optical rotations were recorded on an Autopol III Rudolph research automatic polarimeter, whereas 
IR spectra were obtained on a Thermo Nicolet Nexus 470 FT-IR spectrometer. NMR spectra were 
measured on a Bruker Avance-500/700 FT 500/700 MHz NMR spectrometer using trimethylsilane 
(TMS) as an internal standard. CD spectra were recorded on J-810-150s spectropolarimeter (Jasco, 
Germany). HRESIMS spectra were recorded on a Bruker micrOTOF II ESI-TOF-MS spectrometer. 
Sephadex LH-20 (18–110 μm) was purchased from Pharmacia Co (Japan), whereas octadecylsilane 
(ODS) (50 μm) was purchased from YMC Co. (Japan). HPLC was performed on a Waters 600 
apparatus using a semi-preparative C-18 Phenomenex Luna 5 μm (10 mm × 250 mm) column and 
monitored by a UV detector (Waters 2475).  
3.2. Bacterial Material and Identification  
The Bacillus subtilis strain B1779 was isolated from a marine sediment sample which was collected 
by a multicore sampler at a depth of 1000 m in the Red Sea, in April 2010. This strain was isolated by 
a standard dilution-plating technique. Bacteria in the sediment were released by vigorous shaking in Mar. Drugs 2012, 10 325 
 
 
autoclaved filtered seawater and inoculated in a serial dilution on 1.5% agar composed of 10 g starch 
and 2 g yeast extract dissolved in 1 L filtered seawater.  According to its 16S rRNA gene sequence 
(accession number: HM585050.1), this strain belongs to Bacillus subitlis group. A voucher strain of 
this Bacillus subtilis strain has been preserved at the Costal Marine Lab, Hong Kong University of 
Science and Technology. Genomic DNA was extracted from the cells using the TaKaRa MiniBEST 
Bacterial Genomic DNA Extraction Kit (TaKaRa, China). The 16S rRNA gene of B1779 was amplified 
by a pair of primers of 8F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1525R (5'-AAGGAGTG 
WTCCARCC-3') with Vent DNA polymerase (NEB) and sequenced using Applied Biosystems 3100 
automated DNA sequencer, as previously described [16,17]. The resulting 16S rRNA gene sequence 
was compared with sequences obtained from the NCBI nucleotide database using BLAST search [18] 
to locate approximate phylogenetic affiliation. 
3.3. Fermentation and Extraction 
The bacterium was cultured in multiple 3 L flasks containing SYT culture medium (1% of starch, 
0.4% of yeast extract and 0.2% tryptone) in seawater at 25 °C with agitation (160 rpm) for 4 days until 
the stationary phase was reached. In total, 20 L of fermented broth were obtained. The bacterial culture 
broth was extracted with an equal volume of ethyl acetate (EtOAc) three times and gave a total of 11 g 
of crude extract. 
3.4. Isolation 
The crude EtOAc extract (11.0 g) was fractionated by ODS open column chromatography eluting 
with a step gradient from 40% methanol in water to 100% methanol to give six fractions (F1–F6). 
UPLC-MS analysis and cytotoxicity bio-assay showed that bioactive isocoumacins were mainly 
concentrated in fractions 3 and 4 (named as F3 and F4). F3 (0.39 g) was separated by semi-preparative 
HPLC with a gradient mobile phase (MeCN-H2O, from 30 % to 50 %) to obtain 5 (3.6 mg), 6 (4.7 mg), 
7 (25.0 mg), 8 (11.5 mg), 9 (18.0 mg), 10 (22 mg) and 11(6.2 mg), respectively. F4 (0.42 g) was 
subjected to Sephadex LH-20 and subsequently separated with semi-preparative HPLC eluting with a 
gradient mobile phase (MeCN-H2O, from 60% to 80%) to yield the compounds 1 (1.9 mg), 2 (1.6 mg), 
3 (3.5 mg) and 4 (4.8 mg), respectively. 
3.5. Spectroscopic Data of Compounds 
3.5.1. Lipoamicoumacin A (1) 
White amorphous powder; [α]
27
D −12.0 (c 0.20, MeOH); IR (KBr) νmax 3432, 3047, 2955, 2925, 
2101, 1794, 1667, 1545, 1462, 1371, 1026 and 974 cm
−1; UV (MeOH) λmax (log ε) 206 (4.22), 247 
(3.44) and 314 (3.29) nm; for 
1H and 
13C NMR data, see Table 1; HREIMS m/z 703.3921 [M + H]
+ 
(calcd. for C36H55N4O10, 703.3913); ESI-MS fragmental ions (m/z 521.2, 407.2, 297.2, 250.1).  
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3.5.2. Lipoamicoumacin B (2) 
White amorphous powder;[α]
27
D 4.0 (c 0.20, MeOH); IR (KBr) νmax 3433, 3304, 2924, 2853, 1790, 
1663, 1540, 1461, 1370, 1020 and 873 cm
−1; UV (MeOH) λmax (log ε) 206 (4.18), 247 (3.45) and 314 
(3.32) nm; for 
1H and 
13C NMR data, see Table 1 in Supporting Information; HREIMS m/z 717.4062 
[M + H]
+, (calcd. for C37H57N4O10, 717.4069); ESI-MS fragmental ions (m/z 521.2, 407.2, 311.2, 250.1). 
3.5.3. Lipoamicoumacin C (3) 
White amorphous powder; [α]
27
D −25.0 (c 0.20, MeOH); IR (KBr) νmax 3424, 3314, 3068, 2926, 
2856, 1793, 1665, 1541, 1463, 1371, 1220, 1166, 1112 and 872 cm
−1; UV (MeOH) λmax (log ε) 206 
(4.13), 247 (3.43) and 314 (3.29) nm; for 
1H and 
13C NMR data, see Table 1 in Supporting Information 1; 
HREIMS  m/z 717.4062 [M + H]
+ (calcd. for C37H57N4O10, 717.4069); ESI-MS fragmental ions   
(m/z 535.3, 407.2, 311.2, 250.1, 183.2). 
3.5.4. Lipoamicoumacin D (4) 
White amorphous powder; [α]
27
D −19.2 (c 0.20, MeOH); IR (KBr) νmax 3432, 3045, 2924, 2856, 
1792, 1664, 1538, 1462, 1368, 1115 and 873 cm
−1; UV (MeOH) λmax (log ε) 206 (4.15), 247 (3.43) and 
314 (3.30) nm; for 
1H and 
13C NMR data, see Table 1 in Supporting Information 1; HREIMS   
m/z 731.4215 [M + H]
+, (calcd. for C38H59N4O10, 731.4222); ESI-MS fragmental ions (m/z 535.3, 
407.2, 325.3, 250.1, 197.2). 
3.5.5. Bacilosarcin C (5) 
White amorphous powder; [α]
27
D −18.0 (c 0.20, MeOH); IR (KBr)νmax 3400, 2959, 2880, 1676, 
1620, 1586, 1464, 1388, 1205, 1138, 1040, 966 and 804 cm
−1; UV (MeOH) λmax (log ε) 206 (4.06), 
247 (3.35) and 314 (3.23) nm; for 
1H and 
13C NMR data, see Table 2 in Supporting Information 1; 
HREIMS  m/z 495.2344 [M + H]
+, (calcd. for C24H35N2O9, 495.2337); ESI-MS fragmental ions   
(m/z 477.2, 285.3, 250.1). 
3.6. Cytotoxicity Assay 
Human HeLa cells were used in the assay; 80 μL of 1 × 10
5/mL cells were planted into 96-microwell 
plates. Twelve hours later the cells were treated with testing samples at various concentrations and 
then incubated at 37 °C for 48 hours. Afterward, the supernatant was removed and 20 μL of MTT  
(2.5 mg mL
−1) were added to each well. After incubation at 37 °C for 4 hours, 100 μL of dimethyl 
sulfoxide (DMSO) were added to each well and incubated for an additional 20 min. The absorbance of 
each well was then measured at 570 nm by a Thermo scientific Multiskan FC multiplate photometer 
(Waltham, MA, USA). 
3.7. Antibacterial Assay 
The antibacterial activities of compound 1–11 were evaluated by MIC assay against Staphylococcus 
aureus, Bacillus subtilis, Loktanella hongkongensis, Peseudomonas aeruginosa and Chromobacterium Mar. Drugs 2012, 10 327 
 
 
violaceum. Briefly, the bacterial strains were inoculated in YP broth (0.2% yeast extract, 0.1% peptone 
and 1.7% sea salts) and were incubated at 28 °C for 12 h. The stock solution of samples were prepared 
at 50 mg/mL in DMSO and further diluted to varying concentrations in 96 well plates that contained 
the incubated microbial strains. After incubation at 28 °C for 24 hours, the absorbance of each well 
was then measured at 600 nm by a Thermo scientific Multiskan FC multiplate photometer.  
4. Conclusion 
Bioassay guided investigation of the Red Sea bacterium Bacillus subtilis has resulted in the 
isolation of four novel lipoamicoumacins, lipoamicoumacin A–D (1–4), together with one new 
bacilosarcin C and six known amicoumacins. Study of the structure-activity relationship indicated that 
the C-12' amide functional groups play a critical role in cytotoxicity and antibacterial activities of 
these amicoumacins. It is particularly noteworthy to mention that lipoamicoumacin A–D (1–4) is the 
first subclass of amicoumacin with a lipoamide side chain to be reported from a natural source. 
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